Menu

U.K. Moves Forward With Three-Parent IVF

The country’s fertility regulator has approved the first application to carry out mitochondrial replacement therapy, which uses biological material from two women and one man to create an embryo.

Mar 20, 2017
Bob Grant

PIXABAYMitochondrial replacement therapy (MRT), also known as three-parent in vitro fertilization, is set to make its way to the clinic in the U.K. Last week (March 16), the country’s Human Fertilisation and Embryo Authority (HFEA) approved the first application for license to perform the procedure. The HFEA granted a license to Newcastle University, where researchers have been studying the technique for several years.

“I can confirm today that the HFEA has approved the first application by Newcastle Fertility at Life for the use of mitochondrial donation to treat patients,” HFEA Chair Sally Cheshire told CNN. “Patients will now be able to apply individually to the HFEA to undergo mitochondrial donation treatment at Newcastle, which will be life-changing for them, as they seek to avoid passing on serious genetic diseases to future generations.”

According to Science, Newcastle has said that numerous families have expressed interest in MRT.

MRT, a technique that has stirred some controversy in bioethics circles, involves the transfer of sperm and/or oocyte pronuclei from a fertilized egg before the zygote forms. The protocol is a way for women that carry the potential for mitochondrial diseases to avoid passing suck maladies on to their offspring.

Last year, a US doctor working in Mexico claimed to have successfully birthed the world’s first baby born using MRT.

September 2018

The Muscle Issue

The dynamic tissue reveals its secrets

Marketplace

Sponsored Product Updates

StemExpress LeukopakâNow Available in Frozen Format

StemExpress LeukopakâNow Available in Frozen Format

StemExpress, a Folsom, California based leading supplier of human biospecimens, announces the release of frozen Peripheral Blood Leukopaks. Leukopaks provide an enriched source of peripheral blood mononuclear cells (PBMCs) with low granulocyte and red blood cells that can be used in a variety of downstream cell-based applications.

New Antifade Mounting Media from Vector Laboratories Enhances Immunofluorescence Applications

New Antifade Mounting Media from Vector Laboratories Enhances Immunofluorescence Applications

Vector Laboratories, a leader in the development and manufacture of labeling and detection reagents for biomedical research, introduces VECTASHIELD® Vibrance™ – antifade mounting media that delivers significant improvements to the immunofluorescence workflow.

Best Practices for Sample Preparation and Lipid Extraction from Various Samples

Best Practices for Sample Preparation and Lipid Extraction from Various Samples

Download this white paper from Bertin Technologies to learn how to extract and analyze lipid samples from various models!

Bio-Rad Launches CHT Ceramic Hydroxyapatite XT Media and Nuvia HP-Q Resin for Process Protein Purification

Bio-Rad Launches CHT Ceramic Hydroxyapatite XT Media and Nuvia HP-Q Resin for Process Protein Purification

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced the launch of two new chromatography media for process protein purification: CHT Ceramic Hydroxyapatite XT Media and Nuvia HP-Q Resin.